نتایج جستجو برای: gemfibrozil

تعداد نتایج: 550  

2003
Philippa J. Talmud Steve Martin George Steiner David M. Flavell David B. Whitehouse Sylvia Nagl Richard Jackson Marja-Riitta Taskinen M. Heikki Frick Markku S. Nieminen Y. Antero Kesäniemi Amos Pasternack Steve E. Humphries Mikko Syvänne

Objective— 1-Antitrypsin (AAT) protects elastic tissue and may play a role in atherogenesis. The association of atherosclerosis progression with common AAT variants was considered in 2 clinical trials. Methods and Results—We examined the association of AAT V213A, S and Z deficiency alleles, and the functional 3 UTR 11478G A with change in minimal luminal diameter, a measure of focal disease, in...

2013
Bernadette A. Tumanan-Mendoza Victor L. Mendoza

Objective: To determine the cost-effectiveness of lipid-lowering therapy in the secondary prevention of cardiovascular events in the Philippines. Methods: A cost-utility analysis was performed by using Markov modeling in the secondary prevention setting. The models incorporated efficacy of lipid-lowering therapy demonstrated in randomized controlled trials and mortality rates obtained from loca...

Journal: :Arteriosclerosis, thrombosis, and vascular biology 1998
R Mukherjee J Strasser L Jow P Hoener J R Paterniti R A Heyman

Peroxisome proliferator-activated receptors (PPARs) and retinoid X receptors (RXRs) are members of the intracellular receptor superfamily. PPARs bind to peroxisome proliferator-response elements (PPREs) as heterodimers with RXR and as such activate gene transcription in response to activators. Fibrates like gemfibrozil are well-known PPARalpha activators and are used in the treatment of hyperli...

Journal: :Arteriosclerosis, thrombosis, and vascular biology 2003
Jean-Pierre Després Isabelle Lemieux Agnès Pascot Natalie Alméras Martine Dumont André Nadeau Jean Bergeron Denis Prud'homme

Protein Levels in Abdominally Obese Men With the Atherogenic Dyslipidemia of the Metabolic Syndrome To the Editor: Recent data from Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) have recently reported that pharmacological treatment with a fibrate (gemfibrozil) significantly reduced coronary heart disease (CHD) risk among men with a history of CHD who had low ...

Journal: :Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 2013
Ana M Sierra Villar Ana C Calpena Campmany Lyda Halbaut Bellowa Monserrat Aróztegui Trenchs Beatriz Clares Naveros

A spectrofluorometric method has been developed and validated for the determination of gemfibrozil. The method is based on the excitation and emission capacities of gemfibrozil with excitation and emission wavelengths of 276 and 304 nm respectively. This method allows de determination of the drug in a self-nanoemulsifying drug delivery system (SNEDDS) for improve its intestinal absorption. Resu...

Journal: :Archives of internal medicine 2002
Hanna Bloomfield Rubins Sander J Robins Dorothea Collins David B Nelson Marshall B Elam Ernst J Schaefer Fred H Faas James W Anderson

BACKGROUND Diabetes mellitus, impaired fasting glucose level, or insulin resistance are associated with increased risk of cardiovascular disease. OBJECTIVES To determine the efficacy of gemfibrozil in subjects with varying levels of glucose tolerance or hyperinsulinemia and to examine the association between diabetes status and glucose and insulin levels and risk of cardiovascular outcomes. ...

2013
Jennifer Settergren Birgit Eiermann Buster Mannheimer

PURPOSE To investigate the extent to which clinicians avoid well-established drug-drug interactions that cause statin-induced myopathy. We hypothesised that clinicians would avoid combining erythromycin or verapamil/diltiazem respectively with atorvastatin or simvastatin. In patients with statin-fibrate combination therapy, we hypothesised that gemfibrozil was avoided to the preference of bezaf...

Journal: :Circulation 2006
James D Otvos Dorothea Collins David S Freedman Irina Shalaurova Ernst J Schaefer Judith R McNamara Hanna E Bloomfield Sander J Robins

BACKGROUND Changes in conventional lipid risk factors with gemfibrozil treatment only partially explain the reductions in coronary heart disease (CHD) events experienced by men in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). We examined whether measurement of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particle subclasses provides additional in...

Journal: :Archives of internal medicine 2006
Leena Tenkanen Matti Mänttäri Petri T Kovanen Hanna Virkkunen Vesa Manninen

BACKGROUND The Helsinki Heart Study was a double-blind, placebo-controlled primary prevention trial among 4081 dyslipidemic middle-aged men to test the efficacy of gemfibrozil in the prevention of coronary heart disease (CHD). After the 5-year trial, the participants were notified of their treatment group and invited to continue or start gemfibrozil therapy free of charge through 1995. Approxim...

2013
Alaa El-Sisi Sahar Hegazy Eman El-Khateeb

Background. Activation of PPAR α modulates cholesterol metabolism and suppresses bile acid synthesis. This study aims to evaluate the effect of PPAR α agonists, fenofibrate, bezafibrate, and gemfibrozil, on acute cholestasis induced by ethinylestradiol (EE) plus chlorpromazine (CPZ) in rats. Method. 100 male albino rats (150-200 gm) were divided randomly into 10 equal groups. Control group rece...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید